CY1110981T1 - Πεπτιδια απευαισθητοποιησης εναντια στα αλλεργιογονα - Google Patents

Πεπτιδια απευαισθητοποιησης εναντια στα αλλεργιογονα

Info

Publication number
CY1110981T1
CY1110981T1 CY20101101127T CY101101127T CY1110981T1 CY 1110981 T1 CY1110981 T1 CY 1110981T1 CY 20101101127 T CY20101101127 T CY 20101101127T CY 101101127 T CY101101127 T CY 101101127T CY 1110981 T1 CY1110981 T1 CY 1110981T1
Authority
CY
Cyprus
Prior art keywords
description
allergyogenes
peptides
preventing
allergy
Prior art date
Application number
CY20101101127T
Other languages
English (en)
Inventor
Roderick Peter Hafner
Paul Laidler
Mark Larche
Original Assignee
Circassia Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40134075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110981(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0715949A external-priority patent/GB0715949D0/en
Priority claimed from GB0716224A external-priority patent/GB0716224D0/en
Priority claimed from GB0723337A external-priority patent/GB0723337D0/en
Application filed by Circassia Limited filed Critical Circassia Limited
Publication of CY1110981T1 publication Critical patent/CY1110981T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Η παρούσα εφεύρεση σχετίζεται με πεπτίδια που περιλαμβάνουν πολλά επίτοπα Τ κυττάρων σύνδεσης με MHC Κλάσης ΙΙ για θεραπεία δημιουργίας ανεκτικότητας.
CY20101101127T 2007-08-15 2010-12-07 Πεπτιδια απευαισθητοποιησης εναντια στα αλλεργιογονα CY1110981T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0715949A GB0715949D0 (en) 2007-08-15 2007-08-15 Peptide with improved solubility
GB0716224A GB0716224D0 (en) 2007-08-20 2007-08-20 Peptides for vaccine
GB0723337A GB0723337D0 (en) 2007-11-28 2007-11-28 Peptide with reduced dimer formation
EP08788348A EP2083856B1 (en) 2007-08-15 2008-08-15 Peptides for desensibilization against allergens

Publications (1)

Publication Number Publication Date
CY1110981T1 true CY1110981T1 (el) 2015-06-11

Family

ID=40134075

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101101127T CY1110981T1 (el) 2007-08-15 2010-12-07 Πεπτιδια απευαισθητοποιησης εναντια στα αλλεργιογονα
CY20151100901T CY1116828T1 (el) 2007-08-15 2015-10-07 Πεπτιδια για απευαισθητοποιηση απο αλλεργιογονα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20151100901T CY1116828T1 (el) 2007-08-15 2015-10-07 Πεπτιδια για απευαισθητοποιηση απο αλλεργιογονα

Country Status (24)

Country Link
US (7) US9340580B2 (el)
EP (4) EP2083856B1 (el)
JP (3) JP5697447B2 (el)
KR (1) KR101699554B1 (el)
CN (2) CN103272227B (el)
AT (1) ATE482721T1 (el)
AU (1) AU2008288283B2 (el)
BR (1) BRPI0815395A2 (el)
CA (1) CA2696563A1 (el)
CY (2) CY1110981T1 (el)
DE (1) DE602008002810D1 (el)
DK (2) DK2190473T3 (el)
EA (2) EA023303B1 (el)
ES (1) ES2402956T3 (el)
HK (2) HK1132194A1 (el)
HR (2) HRP20100662T1 (el)
IL (1) IL203943A (el)
MX (1) MX2010001779A (el)
NZ (2) NZ583361A (el)
PL (1) PL2083856T3 (el)
PT (2) PT2083856E (el)
SI (2) SI2083856T1 (el)
WO (4) WO2009022154A2 (el)
ZA (2) ZA201001056B (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
US9340580B2 (en) 2007-08-15 2016-05-17 Circassia Limited Peptide with multiple epitopes
JP5705113B2 (ja) * 2008-08-15 2015-04-22 サーカッシア リミテッド Ｉｌ−１０産生の刺激のためのアレルゲン由来のｔ細胞抗原
EP2444100A3 (en) * 2008-08-15 2012-07-25 Circassia Limited Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
JP5746053B2 (ja) 2009-02-05 2015-07-08 サーカッシア リミテッド ワクチン用ペプチド
US8691522B2 (en) 2009-10-08 2014-04-08 Aeon Medix Inc. Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
CN105061571A (zh) * 2010-01-14 2015-11-18 默克专利股份公司 因脯氨酸残基突变而具有降低变应原性的真禾本科第5组变应原的变体
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
CN103327988B (zh) * 2010-06-03 2016-06-08 阿尔卡贝洛股份公司 包含螨过敏原提取物的药品及其制备方法
WO2012038540A2 (en) * 2010-09-24 2012-03-29 Alergenetica Sl Peptides
EP2460824A1 (en) * 2010-12-01 2012-06-06 Biomay Ag Hypoallergenic polypeptides for the treatment of house dust mite allergy
WO2012149393A2 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
ES2659186T3 (es) * 2011-06-15 2018-03-14 Asit Biotech S.A. Procedimiento de producción de alérgenos hidrolizados
AU2012290306B2 (en) 2011-07-29 2017-08-17 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
GB201208293D0 (en) 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
GB201209868D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Alternaria peptides
GB201209862D0 (en) 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
CA2889784A1 (en) 2012-10-30 2014-05-08 Monash University Novel immunotherapeutic molecules and uses thereof
EA201592103A3 (ru) 2013-05-03 2016-08-31 Селекта Байосайенсиз, Инк. Способы и композиции для усиления cd4+ регуляторных t-клеток
US20160130311A1 (en) * 2013-06-05 2016-05-12 Maria R. Diaz-Torres T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy
AU2014276484B2 (en) * 2013-06-06 2018-01-25 Anergis S.A. Contiguous overlapping peptides for treatment of house dust mites allergy
KR20160075532A (ko) 2013-09-25 2016-06-29 아라백스 피티와이 엘티디 신규한 면역치료제 조성물 및 이의 용도
CA2933552A1 (en) 2013-12-23 2015-07-02 Alk-Abello A/S Peptide combinations and uses thereof in treating dust mite allergy
KR20160138283A (ko) 2014-03-31 2016-12-02 베링거잉겔하임베트메디카게엠베하 개선된 모듈러 항원 운반 분자 및 이의 용도
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
KR20200020966A (ko) * 2015-03-30 2020-02-26 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 면역용 펩티드, 면역용 펩티드의 제조 방법, 그것을 포함하는 면역 질환용 의약 조성물, 및 면역 질환의 치료 방법
MX2018003850A (es) 2015-09-30 2018-06-15 Boehringer Ingelheim Vetmedica Gmbh Moleculas de transporte de antigeno modular mejoradas y sus usos en animales.
KR101858840B1 (ko) 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
NZ760884A (en) 2017-07-18 2023-05-26 Nestle Sa Methods for making mixed allergen compositions
US20200353076A1 (en) * 2017-09-18 2020-11-12 Sutro Biopharma, Inc. Anti-folate receptor alpha antibody conjugates and their uses
CN108078891B (zh) * 2017-12-28 2021-05-07 昆明赛诺制药股份有限公司 一种含美洲大蠊精提物的保湿修复洗面奶
CN107970199B (zh) * 2018-01-03 2021-05-07 昆明赛诺制药股份有限公司 一种含美洲大蠊精提物的牙膏
JP2022519817A (ja) 2019-01-23 2022-03-25 ビフォー ブランズ，インコーポレイテッド 混合アレルゲン組成物の製造方法
CN117362453B (zh) * 2023-12-08 2024-02-27 山东硕景生物科技有限公司 一种Derf1重组抗原、其制备方法及应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3174456D1 (en) 1980-07-18 1986-05-28 Du Pont Monothioglycerol as thiol-protector in lyophilized materials
US4442212A (en) * 1980-11-10 1984-04-10 E. I. Du Pont De Nemours & Company Monothioglycerol as thiol-protector in lyophilized materials
US5126399A (en) * 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
US4906564A (en) * 1987-03-13 1990-03-06 The United States Of America As Represented By The Secretary Of The Army Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens
AU624077B2 (en) * 1987-06-17 1992-06-04 Institute For Child Health Research Cloning of mite allergens
FI891226A (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
ES2013359A6 (es) 1988-11-04 1990-05-01 Corporacion Biolog Farmaceutic Procedimiento para la fabricacion de alergenos inmunogenicos polimerizados.
CA1340977C (en) 1988-11-15 2000-04-25 Monty Krieger Scavenger receptor protein and antibody thereto
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
CA2073045C (en) 1989-11-03 2007-05-22 Malcolm L. Gefter A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
US5547669A (en) * 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
US5433948A (en) * 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
WO1992004445A1 (en) * 1990-09-11 1992-03-19 The Western Australian Research Institute For Child Health Ltd. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
JP2632603B2 (ja) 1991-03-12 1997-07-23 アサヒビール株式会社 ヒト抗ＤｅｒｆＩＩＩｇＥ抗体が結合するペプチド
US6982326B1 (en) * 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6555116B1 (en) 1991-10-12 2003-04-29 Regents Of The University Of California Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
HU220462B1 (hu) * 1991-10-16 2002-02-28 Immulogic Pharmaceutical Corp. A Dermatophagoides nemzetség allergénjéből származó peptidek, ezeket tartalmazó gyógyszerkészítmények és eljárás házi poratka-érzékenység kimutatására
US7288256B1 (en) * 1991-10-16 2007-10-30 Merck Patent Gmbh T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
WO1994004572A1 (en) 1992-08-14 1994-03-03 Torii & Co., Ltd. Allergenic peptide
ATE318902T1 (de) * 1992-12-31 2006-03-15 Immulogic Pharma Corp Allergene proteine und peptide von hundhautanhangsgebilden und ihre verwendung
US5697103A (en) 1993-01-11 1997-12-16 Personal Expression I, Inc. Therapeutic glove
US6849427B1 (en) * 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
AU684501B2 (en) 1993-03-12 1997-12-18 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
EP0694067B1 (en) * 1993-04-14 2006-02-08 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
JPH09509135A (ja) 1993-06-02 1997-09-16 ティーヴィダブリュー テレソン インスティテュート フォー チャイルド ヘルス リサーチ 免疫寛容の誘導における利用のためのクリプティックペプチド
JPH09504167A (ja) 1993-08-13 1997-04-28 イミュロジック ファーマスーティカル コーポレイション ドクムギ花粉アレルゲンのｔ細胞エピトープ
US6180771B1 (en) * 1993-12-08 2001-01-30 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor
JPH07215996A (ja) 1994-01-31 1995-08-15 Torii Yakuhin Kk ダニアレルゲンのｂ細胞エピトープ
KR100379161B1 (ko) * 1994-04-14 2003-06-11 이뮤로직 파마시티컬 코포레이션 집먼지진드기에의한알레르기를치료하기위한의학적펩티드조성물
US5968526A (en) * 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
US6759234B1 (en) * 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
DE19545662C2 (de) * 1995-12-07 1998-11-26 Mannesmann Sachs Ag Selbstpumpendes hydropneumatisches Federbein mit innerer Niveauregulierung
EP1612555B1 (en) 1996-03-21 2008-10-22 Circassia Limited Cryptic peptides for use in inducing immunologic tolerance
WO1999032135A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
WO1999034826A1 (en) 1998-01-09 1999-07-15 Circassia Limited Methods and compositions for desensitisation
FR2806727A1 (fr) 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
BRPI0113400B1 (pt) 2000-08-21 2018-05-15 Apitope Technology Bristol Método para seleção de peptídeo
AU2001286996A1 (en) * 2000-08-31 2002-03-13 Chiron Corporation Stabilized fgf formulations containing reducing agents
NZ525820A (en) * 2000-11-16 2005-01-28 Alk Abello As Mutant allergens
US7786257B2 (en) * 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
FR2820425B1 (fr) 2001-02-08 2004-01-02 Commissariat Energie Atomique Melange de peptides issus d'une proteine nef et leurs applications
JP4812951B2 (ja) * 2001-03-21 2011-11-09 一般財団法人化学及血清療法研究所 特異性不明のｔ細胞のクローン化法及びその認識ペプチドリガンドの同定方法
GB0108752D0 (en) 2001-04-06 2001-05-30 Isis Innovation Peptide epitopes and uses thereof
US20040202654A1 (en) 2001-04-09 2004-10-14 Mayo Foundation For Medical Education & Research Methods and materials for cancer treatment
AUPR775401A0 (en) * 2001-09-18 2001-10-11 Monash University Novel Epitopes and Uses Thereof
EP1450847B1 (en) 2001-11-13 2010-09-29 Genentech, Inc. APO2 ligand/ TRAIL formulations and uses thereof
CA2469078A1 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
AUPS148202A0 (en) * 2002-04-02 2002-05-09 Monash University Immunotherapeutic and immunoprophylactic reagents
FR2841906B1 (fr) 2002-07-05 2006-08-18 Stallergenes Sa Molecule d'acide nucleique codant une preproproteine d'allergene d'un acarien du genre dermatophagoides ou euroglyphus et son utilisation pour la production dudit allergene dans les plantes
EP2351770A1 (en) * 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
US20040071718A1 (en) * 2002-09-18 2004-04-15 Jaw-Ji Tsai Local nasal immunotherapy for allergen-induced airway inflammation
CA2518187A1 (en) 2003-03-07 2004-09-16 London Health Sciences Centre Reseach, Inc. Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
ES2289528T3 (es) 2003-06-26 2008-02-01 Merck Patent Gmbh Proteinas de trombopoyetina con propiedades mejoradas.
GB0315754D0 (en) * 2003-07-04 2003-08-13 Univ Aberdeen Pharmaceutical compositions
US20050053615A1 (en) * 2003-07-16 2005-03-10 Best Elaine A. Variants of mite group 1 allergens for the treatment of house dust mite allergy
AU2004288854B2 (en) 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
WO2005103082A2 (en) 2004-04-23 2005-11-03 Novozymes A/S Group 1 mite polypeptide variants
US8057800B2 (en) * 2004-06-10 2011-11-15 Circassia Limited Immunointeractive molecules and uses thereof
US20060029551A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
EP1808497B1 (en) * 2004-09-27 2014-10-08 Hayashibara Co., Ltd. Isocyclomaltooligosaccharide, isocyclomaltooligosaccharide synthase, process for producing them and use thereof
AU2006210895A1 (en) 2005-02-01 2006-08-10 Attenuon, Llc Compositions containing the anti-angiogenic PHSCN-peptide
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
JP2009508118A (ja) * 2005-09-15 2009-02-26 アルク−アベッロ エイ／エス アレルゲンの定量方法
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
GB0609121D0 (en) 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
ES2657480T3 (es) * 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
WO2008115428A2 (en) 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University A scaleable manufacturing process for cysteine endoprotease b, isoform 2
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
US9340580B2 (en) * 2007-08-15 2016-05-17 Circassia Limited Peptide with multiple epitopes
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders

Also Published As

Publication number Publication date
DK2190473T3 (da) 2013-03-25
HRP20100662T1 (hr) 2011-01-31
WO2009022156A2 (en) 2009-02-19
ES2402956T3 (es) 2013-05-10
KR101699554B1 (ko) 2017-01-25
US9744222B2 (en) 2017-08-29
JP6040207B2 (ja) 2016-12-07
US8551493B2 (en) 2013-10-08
PT2397154E (pt) 2015-10-29
BRPI0815395A2 (pt) 2015-02-10
EP2397154B1 (en) 2015-07-15
JP2010536333A (ja) 2010-12-02
AU2008288283B2 (en) 2013-01-31
EP2397154A2 (en) 2011-12-21
EP2286833A2 (en) 2011-02-23
ATE482721T1 (de) 2010-10-15
CA2696563A1 (en) 2009-02-19
DK2083856T3 (da) 2011-01-24
US8652485B2 (en) 2014-02-18
NZ583362A (en) 2012-06-29
US9340580B2 (en) 2016-05-17
WO2009022157A2 (en) 2009-02-19
MX2010001779A (es) 2010-07-06
US20130336999A1 (en) 2013-12-19
IL203943A (en) 2013-05-30
WO2009022157A3 (en) 2009-06-04
EA201070271A1 (ru) 2010-12-30
CN103272227B (zh) 2014-12-10
SI2190473T1 (sl) 2013-05-31
JP5697447B2 (ja) 2015-04-08
JP2017061455A (ja) 2017-03-30
PT2083856E (pt) 2010-12-23
EP2083856A2 (en) 2009-08-05
JP2015057393A (ja) 2015-03-26
SI2083856T1 (sl) 2011-02-28
US20100260805A1 (en) 2010-10-14
KR20100068252A (ko) 2010-06-22
AU2008288283A1 (en) 2009-02-19
CN101820907B (zh) 2013-05-01
HK1164700A1 (en) 2012-09-28
CN101820907A (zh) 2010-09-01
EP2286833A3 (en) 2011-09-14
EP2083856B1 (en) 2010-09-29
US20140186403A1 (en) 2014-07-03
WO2009022154A2 (en) 2009-02-19
WO2009022156A3 (en) 2009-04-30
ZA201001054B (en) 2011-04-28
CN103272227A (zh) 2013-09-04
US20110123558A1 (en) 2011-05-26
ZA201001056B (en) 2011-04-28
WO2009022154A3 (en) 2009-06-04
EP2190473B1 (en) 2013-01-16
HRP20130270T1 (hr) 2013-04-30
EA023303B1 (ru) 2016-05-31
CY1116828T1 (el) 2017-03-15
EA201070270A1 (ru) 2010-08-30
WO2009022155A3 (en) 2009-06-04
US20100298239A1 (en) 2010-11-25
WO2009022155A2 (en) 2009-02-19
US20170157226A1 (en) 2017-06-08
EA018110B1 (ru) 2013-05-30
DE602008002810D1 (de) 2010-11-11
EP2190473A2 (en) 2010-06-02
PL2083856T3 (pl) 2011-04-29
EP2397154A3 (en) 2012-04-04
HK1132194A1 (en) 2010-02-19
NZ583361A (en) 2012-10-26
US20160289281A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
CY1110981T1 (el) Πεπτιδια απευαισθητοποιησης εναντια στα αλλεργιογονα
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
NL300915I2 (nl) Daratumumab
MX2009006846A (es) Derivados de tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias.
MX339402B (es) Composiciones y metodos que comprenden variantes de serina proteasa.
BRPI0720328A2 (pt) Composição tensoativa e detergente ou limpador.
FI20055622A0 (fi) Järjestely pölyn käsittelemiseksi
ATE504334T1 (de) Haarbehandlungszusammensetzungen
EA201201406A1 (ru) Фунгицидные смеси ii, содержащие хиназолины
ATE474886T1 (de) Polythioether-aminharze und zusammensetzungen damit
EA201171001A1 (ru) Пептиды трав для вакцины
DE602006010424D1 (de) Schweisshemmende oder desodorierende zusammensetzungen
ATE536033T1 (de) Vlan-nummerierung in zugangsnetzen
EA201201402A1 (ru) Фунгицидные смеси ii, содержащие хиназолины
AT503071A3 (de) Pflanzenkläranlage
FI20055163A0 (fi) Hoitopöytä
TR200705455U (tr) Köşe koruyucu plastik.
FI7048U1 (fi) Sahakokoonpano
FIU20050124U0 (fi) Jätevedenpuhdistamo
UA11947S (uk) Респіратор